Dr. Timothy Brant is a practicing radiation oncologist from Crystal River, Florida. He received his undergraduate and medical degrees from the University of Florida in Gainesville. He was on the radiation oncology faculty for five years before moving to central Florida where he joined the Robert Boissoneault Oncology Institute. RBOI has offices in Ocala, the Villages and Citrus county. Dr. Brant is married and has three sons, one of whom is an osteopathic dermatology resident. He is an avid runner and enjoys hunting and fishing. He has given numerous presentations and publications and has a special interest in radiation for skin cancers. He has successfully treated hundreds of patients with skin cancers from early stage to widely metastatic disease.

Treating Skin Cancer with Radiation: Traditional and New Approaches

This lecture will discuss traditional radiation for skin cancer versus new approaches which entail the use of electronic brachytherapy machines, radiation techniques and outcomes.

Objectives:

1. Provide attendees with an understanding of basic principles of irradiation for skin cancer as related to traditional and new approaches
2. Provide attendees with an understanding of indications for irradiation in terms of traditional and new approaches
3. Provide attendees with an understanding of clinical data as related to traditional and new EBT in terms of outcome and complications

Needs: 

1. New advances in dermatologic treatment
2. Development of new technology

References: 

• J. Locke, S. Karimpour et al. “Radiotherapy for epithelial Skin Cancers” Int. J RadiBiolPhysat Oncol 2001;51:748-55. 
• L Krapp, CJ Balmucki et al. “Mohs Resection and Postoperative Radiotherapy for Head and Neck Cancers with Incidental Perineural Invasion” Am J Otolaryngol. 2013;5:373-377. 
• A. Cognetta, W. Mendenhall eds. “Radiation Therapy for Skin Cancer”. Springer, New York 2013.

Core competencies: 2, 3, 5, 6 

Disclosures: Off-label: Electronic Brachytherapy - Approved by FDA. Insurance carriers consider investigational because of lack of level 1 clinical data.